Breaking news today as, for the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair genes. Read more about the new approval.

VN:F [1.9.17_1161]
Rating: 0.0/5 (0 votes cast)
Share This Post